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Abstract
Breast cancer is the most common malignancy afflicting women
from Western cultures. Developments in breast cancer molecular
and cellular biology research have brought us closer to
understanding the genetic basis of this disease. Recent advances
in microarray technology hold the promise of further increasing our
understanding of the complexity and heterogeneity of this disease,
and providing new avenues for the prognostication and prediction
of breast cancer outcomes. These new technologies have some
limitations and have yet to be incorporated into clinical use, for
both the diagnosis and treatment of women with breast cancer.
The most recent application of microarray genomic technologies to
studying breast cancer is the focus of this review.
Introduction
Mortality from breast cancer results from the ability of some
tumors to metastasize to distant sites. Selecting patients with
micrometastases at diagnosis is crucial for clinicians in
deciding who should and who should not receive toxic and
expensive adjuvant chemotherapy to eradicate these
metastatic cells. Although many individual biomarkers were
originally attractive, over the years most have failed to
become clinically useful. In addition, the management of
breast cancer has changed, with most node-negative patients
now undergoing systemic adjuvant therapy because we
cannot precisely determine an individual’s risk of recurrence.
A majority of node-negative patients are being unnecessarily
overtreated because if they were left systemically untreated,
only about 25% of node-negative patients would ever
develop recurrence. There is therefore a crucial need to
identify patients with a sufficiently low risk of breast cancer
recurrence to avoid further treatment. In addition, in patients
at risk of recurrence and in need of therapy, optimal
therapeutic selection is an increasingly important objective.
Recent developments in applying microarray technologies to
breast tumor samples suggest that these new techniques
might provide for the transition of molecular biological
discoveries to clinical application, and will generate clinically
useful genomic profiles that more accurately predict long-
term outcome for individual breast cancer patients.
Background
Until recently, evaluations of prognostic and predictive factors
have considered one factor at a time or have used small
panels of markers. However, with the advent of new genomic
technologies such as microarrays capable of simultaneously
measuring thousands of genes or gene products, we are
beginning to construct molecular fingerprints of individual
tumors so that accurate prognostic and predictive assess-
ments of each cancer can be made. Clinicians might one day
base clinical management on each woman’s personal
prognosis and predict the best individual therapies from the
genetic fingerprint of each individual cancer.
Breast cancer is characterized by a heterogeneous clinical
course. A major goal of recent studies is to determine
whether RNA microarray expression profiling, or DNA array
gene amplification or gene loss patterns, can accurately
predict an individual’s long-term potential for recurrence from
breast cancer, so that appropriate treatment decisions can be
made. Microarrays can be used to measure the mRNA
expression of thousands of genes at one time or to survey
genomic alterations that might distinguish between molecular
phenotypes associated with long-term recurrence-free
survival or clinical response to treatment. These new
technologies have been successfully applied to primary
breast cancers and may eventually outperform currently used
clinical parameters in predicting disease outcome.
Because the RNA expression microarray technology provides
a method for monitoring the RNA expression of many
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thousands of human genes at one time, there was
considerable anticipation that it would quickly and easily
revolutionize our approaches to cancer diagnosis, prognosis,
and treatment. The reality remains extremely promising but it
is also complex. A potential complication in the application of
microarray technology to samples of primary human breast
tumors is the presence of variable numbers of normal cells,
such as stroma, blood vessels, and lymphocytes, in the
tumor. Indeed, it has been demonstrated, with the use of
gross analysis of human breast cancer specimens compared
with breast cancer cell lines, that the tumors expressed sets
of genes in common not only with these cell lines but also
with cells of hematopoietic lineage and stromal origin [1].
Laser capture microdissection has also been used
successfully to isolate pure cell populations from primary
breast cancers for array profiling [2]. In their seminal paper,
Sgroi and colleagues [2] used laser capture microdissection
to isolate morphologically ‘normal’ breast epithelial cells,
invasive breast cancer cells, and metastatic lymph node
cancer cells from one patient, and were able to demonstrate
the feasibility of using microdissected samples for array
profiling, and also for following the potential progression of
cancer in this patient. However, with the emerging data
supporting important roles for the surrounding stroma in
breast cancer progression, and the labor-intensive and
technically challenging nature of laser capture technology
with subsequent amplification of RNA for quantification, most
published investigations so far have evaluated total gene
expression to identify prognostic profiles, as will be described
in the next section.
Molecular classification of breast cancer
A study of sporadic breast tumor samples by Perou and
colleagues [1] was the first to show that breast tumors could
be classified into subtypes distinguished by differences in
their expression profiles. Using 40 breast tumors, and 20
matched pairs of samples before and after doxorubicin
treatment, an ‘intrinsic gene set’ of 476 genes were selected
that were more variably expressed between the 40 sporadic
tumors than between the paired samples. This intrinsic gene
set was then used to cluster and segregate the tumors into
four major subgroups: a ‘luminal cell-like’ group expressing
the estrogen receptor (ER); a ‘basal cell-like’ group
expressing keratins 5 and 17, integrin β4, and laminin, but
lacking ER expression; an ‘Erb-B2-positive’ group; and a
‘normal’ epithelial group (Fig. 1).
In a subsequent study with 38 additional cancers, the
investigators found the same subgroups as before [3], except
that the luminal, ER-positive group was further subdivided
into subsets with distinctive gene expression profiles. In
univariate survival analysis, performed on the 49 patients
diagnosed with locally advanced disease but without
evidence of distant metastasis, ER positivity was not a
significant prognostic factor on its own, but the luminal-type
group enjoyed a more favorable survival than the other
groups. Conversely, the basal-like group had a significantly
poorer prognosis. Although small and exploratory, this study
suggests that important differences in outcome can be
ascertained from microarray expression profiling.
An interesting study was reported by Gruvberger and
colleagues [4], who profiled 58 grossly dissected primary
invasive breast tumors and used artificial neural network
analysis to predict the ER status of the tumors on the basis of
their gene expression patterns. They then determined which
specific genes were the most important for ER classification.
By comparison with SAGE (serial analysis of gene
expression) data from estradiol-stimulated breast cancer
cells, they determined that only a few genes of the many
genes that were associated with ER expression in tumors
were indeed estrogen-responsive in cell culture. This obser-
vation lends further support to the hypothesis developed by
Perou and colleagues that basic cell lineages, such as the
luminal ER-positive cell type, can be partly explained by
observed genomic gene expression patterns rather than by
downstream effectors of only one pathway, such as the ER.
Figure 1
Supervised classification on prognosis signatures (van ’t Veer). The 78
tumors are listed vertically, and the 70 ‘prognostic’ genes horizontally.
The expression levels are shown in red (expression levels above the
mean for the gene) and green (levels below the mean for the gene).102
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Prognostic implications
Microarrays have also been used to predict lymph node
status and very short-term relapse-free survival in two groups
(n = 37 and 52, respectively) of heterogeneously treated
patients [5]. Although prediction of nodal status is of limited
interest clinically, the study uses innovative statistical
methods, rigorously generates estimates of future classifier
performance and further demonstrates the feasibility of
accurate prediction of tumor biology with expression arrays.
In a more focused and somewhat more clinically relevant
study, van ’t Veer and colleagues [6] used RNA expression
microarray analyses to identify a 70-gene prognostic gene
signature (‘classifier’) in young, untreated, axillary lymph node-
negative patients by using a training set of 44 tumors with a
good outcome (disease-free more than 5 years) and 34 with
a poor outcome (distant relapse in less than 5 years), and
then tested the classifier in a validation set of 19 tumors. The
same group [7] has now extended the study to a total of 295
young (less than 53 years of age), stage I to II breast cancer
patients with both node-negative and node-positive disease,
using the 70-gene classifier [6]. The microarray-based
predictions are consistent with, and perhaps better than,
estimates that can be obtained with current prognostic
indices.
Genetic susceptibility
A few studies have used new genomic approaches for the
study of inherited breast cancer (reviewed in [8]). There is
accumulating evidence, both epidemiological and histo-
logical, that tumors arising as a result of mutations in the two
breast cancer susceptibility gene families (BRCA1 and
BRCA2) are biologically distinct. For instance, BRCA1 breast
cancers are most often ER and progesterone receptor (PR)-
negative, but BRCA2 cancers more often tend to be positive
for these receptors [9]. In a seminal paper published by
Hedenfalk and colleagues [8], seven tumors each from
BRCA1 and BRCA2 gene mutation carriers, or sporadic
breast cancers, were compared by expression microarray
analysis. They found that the gene expression profiles of the
three tumor groups differed significantly from each other,
underscoring the fundamental differences between BRCA1
and BRCA2 mutation-associated tumors. Of course a
potential confounding issue was the differential distribution of
ER between the BRCA1 and BRCA2 tumors. However, even
after the removal of ER/PR-associated genes from the
analysis, the two inherited tumor groups were still discernible.
Thus, ER status alone does not fully explain the observed
differences in gene expression profiles. Although this study is
obviously very small, and other confounding issues such as
tumor stage, grade, and treatment were not able to be
considered, it does set a foundation for larger validation
studies to confirm differential genes that could then provide
important clues to the etiology of inheritable breast cancer.
Microarrays are also being studied as a way of predicting
response to systemic therapy. The neoadjuvant setting is
especially attractive for these studies for several reasons
including early assessment of response to therapy, biopsiable
access to the primary tumor, and considerably reduced
sample sizes compared with those required in the adjuvant
setting.
Predictive implications
Methods for assessing response in neoadjuvant trials remain
problematic. Clinical response to neoadjuvant chemotherapy
is a validated surrogate marker for improved survival [10,11].
Women who achieve pathologic complete response are most
likely to have the best clinical outcome, although survival is
still improved in those who clinically respond who do not
achieve pathologic complete response.
In an early study, Buchholz and colleagues [12] obtained
sufficient RNA from core biopsies of five patients to perform
serial microarray expression profiles and showed that, despite
differences in therapy, patients with good pathological
responses to neoadjuvant treatment seemed to have gene
profiles that clustered distinctly differently from those of
patients who were poor responders to treatment. More
recently, Chang and colleagues [13] have shown that gene
profiling can be used in accurately predicting response to
neoadjuvant docetaxel. The study enrolled 24 subjects,
extracted sufficient RNA from all core needle biopsies and
constructed a 92-gene predictor of response (Fig. 2). In a
complete cross-validation analysis, which gives an unbiased
estimate of performance on future samples, the classifier
correctly identified 10 of 11 responders and 11 of 13 non-
responders for an overall accuracy of 88%. In a small
validation set, this 92-gene classifier successfully predicted
response in six patients. This compares very favorably with
the best existing predictive factors for response to specific
therapy, and strongly suggests that after appropriately
extensive validation, microarray profiling will be useful for
treatment selection. A second neoadjuvant study was
recently published with the use of cDNA arrays to develop
predictors for paclitaxel, fluorouracil, doxorubicin, and
cyclophosphamide, involving 24 samples. A classifier with 74
markers was developed, with 78% accuracy, suggesting that
transcriptional profiling has the potential to identify a gene
expression pattern in breast cancer that might lead to
clinically useful predictors of chemotherapy response [14].
However, we acknowledge that studies to construct and
validate array-based prognostic and predictive ‘markers’ are
complex. These studies must address all of the concerns
associated with ordinary, single-gene markers as well as
several considerations unique to array studies. Recommen-
dations for the development of array-based prognostic
classifiers have recently been enunciated by Simon and
colleagues [15]. Among the most important points, they
recommend that studies should include the following: first,
adequately large sample sizes in both training and validation
sets; second, a complete iteration of the entire classifier103
construction process in estimating cross-validated prediction
rates; third, head-to-head comparison of alternative classifiers
on the same data set; and fourth, inclusion of the full diversity
of cases in any validation sets. In addition, gene expression
patterns can be confounded by several other factors
including ovarian ablation in premenopausal ER-positive
patients, and different mechanisms of action of combination
chemotherapies. Groups of patients with different character-
istics such as menopausal and ER status or HER-2 over-
expression might be necessary for the definitive deter-
mination of classifying patterns in these subsets of patients.
Conclusion
The goal of comprehensive, genome-wide approaches is to
identify clinically useful genetic profiles that will accurately
predict the outcome of therapy and the prognosis of patients
with breast cancer. Despite improvements in technology,
complex mechanisms driving the evolution of breast cancer
continue to present challenges for the use of genomic
approaches in the better understanding of breast and other
cancers. This, combined with our use of different markers,
methods, tumors (for example differing ER and HER2), and
measurements of clinical outcomes, impedes the
development of a consensus about predictive and prognostic
markers for breast cancer.
As this field matures, genomic studies examining identical
breast tumor sets with multiple complementary technologies
(for example loss of heterozygosity, comparative genetic
hybridization, and gene expression array analyses) will prove
essential in unraveling the genetic heterogeneity charac-
teristic of this disease. A combined genomic approach is
necessary to define the underlying heterogeneous complexity
that is characteristic of breast cancer. These data should lead
to the identification and characterization of breast cancer
subtypes, the definition of the malignant potential of a given
lesion, and the prediction of its sensitivity to specific
therapies. These multidisciplinary approaches should contribute
to a better biological understanding of, and therefore
improved clinical management of, breast cancer.
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Figure 2
Hierarchical clustering of genes correlated with response to docetaxel. Sensitive tumors (S) are defined as those with 25% residual disease or less
(shown as blue bars), and resistant tumors (R) are defined as those with greater than 25% residual disease (shown as red bars). The expression
levels are shown in red (expression levels above the mean for the gene) and blue (levels below the mean for the gene).104
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